Visceral Pain: Introduction
- Osteogenesis imperfecta (OI) is a genetic disorder in which the bones fracture (break) easily. Sometimes, the fracture occurs for no known reason. OI can also lead to weak muscles, brittle teeth, a curved spine, and hearing loss. Symptoms of osteogenesis imperfecta can range from mild to severe; it may vary from person to person.
- OI is caused by one of several genes that aren’t working properly. When these genes don’t work, they affect the production of collagen, a protein that makes the bones strong.
- The four types of OI are: Osteogenesis Imperfecta Type I, Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III, and Osteogenesis Imperfecta Type IV. Of these, Osteogenesis type I is highly common and usually the mildest form of OI.
Request a PDF Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79407
Key Drivers of Global Osteogenesis Imperfecta Treatment Market
- Increase in number of patients with OI is likely to drive the market during the forecast period. According to National Organization for Rare Disorders, OI type I is estimated to occur in one in 30,000 live births. OI type II is estimated to occur in one in 60,000 live births. The overall prevalence of all types of OI is estimated at .5 per 10,000 individuals in the U.S. Approximately 20,000 to 50,000 individuals in the U.S. have OI.
- Currently, available treatment options such as physical therapy, bracing, and medication (Bisphosphonates) do not treat the OI condition effectively. Therefore, several researchers are involved in research & development to develop novel therapies and treatment, which is expected to drive the global osteogenesis imperfecta treatment market.
- Strong product pipeline for osteogenesis imperfecta is likely to boost the market during the forecast period. Currently, Amgen Inc. has one innovative drug product, i.e. Prolia, in phase III for the treatment of OI disease.
Request a Sample of Osteogenesis Imperfecta Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=79407
Teriparatide segment to expand significantly
- In terms of drug class, the global osteogenesis imperfecta treatment market can be segregated into teriparatide, denosumab, and others
- The teriparatide segment accounted for a significant share of the global osteogenesis imperfecta treatment market in 2019. Increase in use of teriparatide drugs in the treatment of OI is likely to propel the segment during the forecast period.
Request for Analysis of COVID19 Impact on Osteogenesis Imperfecta Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79407
Oral to be highly lucrative segment
- Based on route of administration, the global osteogenesis imperfecta treatment market can be classified into parenteral, oral, and others
- The oral segment accounted for a significant share of the global market, in terms of revenue, in 2019. The trend is likely to continue during the forecast period. Most products can be administered through the oral route, which is likely to boost the segment.
Hospitals pharmacies to be highly promising segment
- Based on distribution channel, the global osteogenesis imperfecta treatment market can be classified into hospital pharmacies, retail pharmacies, and online sales
- The hospital pharmacies segment accounted for a prominent share of the market, in terms of revenue, in 2019. The segment is anticipated to expand during the forecast period as most major products are prescription products that are available at hospital pharmacies.
Pre-Book Osteogenesis Imperfecta Treatment Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79407<ype=S
North America to Dominate Global Osteogenesis Imperfecta Treatment Market
- In terms of region, the global osteogenesis imperfecta treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America dominated the global osteogenesis imperfecta treatment market in 2019. The trend is projected to continue during the forecast period. The region’s dominance can be attributed to the presence of major market players and increase in focus on research and development activity in the region.
- The osteogenesis imperfecta treatment market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to an increase in adoption of new products and a rise in number of patients suffering from osteogenesis imperfecta.
Key Players Operating in Global Osteogenesis Imperfecta Treatment Market
The global osteogenesis imperfecta treatment market was highly fragmented in 2019.
More Trending Reports by Transparency Market Research:
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
